I am a Healthcare Professional outside the US and UK

I am a Healthcare Professional outside the US and UK

Click here for international medical scientific information about Oncology for Healthcare Professionals.

I am not a Healthcare Professional and I am outside the US and the UK

I am not a Healthcare Professional and I am outside the US and the UK

Click here for general international information for patients, caregivers and the general public.

Country-specific medical scientific information

Country-specific medical scientific information

Country-specific medical scientific information for Healthcare Professionals.

This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

InOncology.com

ESMO 2018

European Society for Medical Oncology Congress 2018

The annual congress of the European Society for Medical Oncology took place between the 19th and the 23rd October. At the meeting, Boehringer Ingelheim hosted a symposium and presented a number of publications highlighting our advances in the treatment of cancer.

Symposium: Treating lung cancer in a rapidly evolving landscape

At this symposium, an international faculty of experts discussed treatment sequencing in EGFR mutation-positive NSCLC, the efficacy of EGFR TKIs in patients with uncommon mutations, and treatment considerations for second-line and beyond in non-mutated, non-squamous NSCLC.

Please see below where you can access materials from our symposium.

Maximilian Hochmair, MD

Sequencing in EGFR-mutated NSCLC: does order matter?

Presenter(s): Maximilian Hochmair, MD
Edward S. Kim, MD

Efficacy of EGFR TKIs in patients with uncommon mutations

Presenter(s): Edward S. Kim, MD
Sanjay Popat, BSc, MBBS, FRCP, PhD

Treating second-line and beyond in non-mutated, non-squamous NSCLC: now and tomorrow

Presenter(s): Sanjay Popat, BSc, MBBS, FRCP, PhD
Publications
Filter by:
Presentation Type
  • All presentation types
  • Oral Presentation
  • Poster Presentation
  • e-Presentation
Tumour Type
  • All tumour types

We also presented a number of publications during the scientific program at ESMO – please see downloadable versions below.

Saturday 20th October 2018
Afatinib* versus erlotinib as second-line treatment of patients with advanced lung squamous cell carcinoma: final analysis of the global phase III LUX-Lung 8 trial
Author(s): Glenwood Goss et al.
Poster Presentation
Tumour Type(s): NSCLC
Presentation Number: 1442P
Efficacy of Afatinib in the clinical practice - First results of the GIDEON trial: a prospective non-interventional study in EGFR mutated NSCLC in Germany
Author(s): Wolfgang Brueckl et al.
Poster Presentation
Tumour Type(s): NSCLC
Presentation Number: 1449P
Phase IV, open-label, multicentre trial of afatinib in patients aged ≥70 yrs with NSCLC harbouring common (Del19/L858R) EGFR mutations: preliminary results
Author(s): Karen Reckamp et al.
Poster Presentation
Tumour Type(s): NSCLC
Presentation Number: 1456P
Phase I study of BI 754111 (anti-LAG-3) plus BI 754091 (anti-PD-1) in patients (pts) with advanced solid cancers, followed by expansion in pts with microsatellite stable metastatic colorectal cancer (mCRC), anti-PD-(L)1-pretreated NSCLC and other solid tumors
Author(s): Melissa Johnson et al.
Poster Presentation
Tumour Type(s): Solid tumours, CRC, NSCLC
Presentation Number: 1243TiP
There are no publications which meet your criteria on this date

Find out more about other oncology events

Click here to find out more about other oncology meetings, congresses, symposia and activities sponsored by Boehringer Ingelheim.

*Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.

 

**Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.

 

© 2018 Boehringer Ingelheim International GmbH. All rights reserved.

 Last updated: October 2018